Cardiomyopathy, Hypertrophic

"Cardiomyopathy, Hypertrophic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

Descriptor ID	D002312
MeSH Number(s)	C14.280.238.100 C14.280.484.150.070.160
Concept/Terms	Cardiomyopathy, Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathies, Hypertrophic Hypertrophic Cardiomyopathies Hypertrophic Cardiomyopathy Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathies, Hypertrophic Obstructive Hypertrophic Obstructive Cardiomyopathies Hypertrophic Obstructive Cardiomyopathy Obstructive Cardiomyopathies, Hypertrophic Obstructive Cardiomyopathy, Hypertrophic

Below are MeSH descriptors whose meaning is more general than "Cardiomyopathy, Hypertrophic".

Diseases [C]
Cardiovascular Diseases [C14]
Heart Diseases [C14.280]
Cardiomyopathies [C14.280.238]
Cardiomyopathy, Hypertrophic [C14.280.238.100]
Heart Valve Diseases [C14.280.484]
Aortic Valve Stenosis [C14.280.484.150]
Aortic Stenosis, Subvalvular [C14.280.484.150.070]
Cardiomyopathy, Hypertrophic [C14.280.484.150.070.160]

Below are MeSH descriptors whose meaning is related to "Cardiomyopathy, Hypertrophic".

Below are MeSH descriptors whose meaning is more specific than "Cardiomyopathy, Hypertrophic".

Cardiomyopathy, Hypertrophic
Cardiomyopathy, Hypertrophic, Familial

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cardiomyopathy, Hypertrophic" by people in this website by year, and whether "Cardiomyopathy, Hypertrophic" was a major or minor topic of these publications.

Bar chart showing 421 publications over 25 distinct years, with a maximum of 31 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	1	2
2002	6	1	7
2003	8	0	8
2004	11	0	11
2005	13	1	14
2006	8	0	8
2007	16	2	18
2008	10	2	12
2009	25	1	26
2010	20	0	20
2011	19	0	19
2012	14	0	14
2013	11	0	11
2014	20	0	20
2015	25	2	27
2016	20	1	21
2017	20	0	20
2018	15	0	15
2019	22	0	22
2020	27	1	28
2021	18	0	18
2022	31	0	31
2023	17	0	17
2024	28	1	29
2025	3	0	3

Below are the most recent publications written about "Cardiomyopathy, Hypertrophic" by people in Profiles.

Fath AR, Aglan A, Maron MS, Phillips JS, Maron BJ, Rowin EJ. Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy. Int J Cardiol. 2025 May 01; 426:133082.

View in: PubMed
Ezenna C, Krishna MM, Joseph M, Pereira V, Nadeem S, Valania G, Goldsweig AM. The Efficacy and Safety of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. Am J Cardiol. 2025 Apr 15; 241:52-60.

View in: PubMed
Massera D, Sherrid MV, Adlestein E, Bokhari N, Alvarez IC, Wu WY, Reuter MC, Maron MS, Maron BJ, Rowin EJ. Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5?Years. J Am Heart Assoc. 2025 Jan 21; 14(2):e037639.

View in: PubMed
Ali SA, Perera G, Laird J, Batorsky R, Maron MS, Rivas VN, Stern JA, Harris S, Chin MT. Single Cell Transcriptomic Profiling of MYBPC3-Associated Hypertrophic Cardiomyopathy Across Species Reveals Conservation of Biological Process But Not Gene Expression. J Am Heart Assoc. 2025 Jan 07; 14(1):e035780.

View in: PubMed
Aimo A, Olivotto I, Todiere G, Barison A, Panichella G, Fiuzat M, Linde C, Lakdawala NK, Desai M, Zannad F, Maron MS. Endpoint Selection in Randomized Clinical Trials for Hypertrophic Cardiomyopathy. JACC Heart Fail. 2025 Feb; 13(2):200-212.

View in: PubMed
Aimo A, Todiere G, Barison A, Tomasoni D, Panichella G, Masri A, Maron MS. Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines. Heart Fail Rev. 2025 Mar; 30(2):315-325.

View in: PubMed
Coats CJ, Masri A, Barriales-Villa R, Abraham TP, Brinkley DM, Claggett BL, Hagege A, Hegde SM, Ho CY, Kulac IJ, Lee MMY, Maron MS, Olivotto I, Owens AT, Solomon SD, Tfelt-Hansen J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Januzzi JL. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. Eur Heart J. 2024 Nov 08; 45(42):4464-4478.

View in: PubMed
Masri A, Choudhury L, Barriales-Villa R, Elliott P, Maron MS, Nassif ME, Oreziak A, Owens AT, Saberi S, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Nagueh SF, Wang A, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Sherrid MV, Abraham TP. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1839-1849.

View in: PubMed
Tahir UA, Kolm P, Kwong RY, Desai MY, Dolman SF, Deng S, Appelbaum E, Desvigne-Nickens P, DiMarco JP, Tiwari G, Friedrich MG, Zelaya-Portillo JH, Jerosch-Herold M, Kim DY, Maron MS, Piechnik SK, Schulz-Menger J, Watkins H, Weintraub WS, Neubauer S, Kramer CM, Jarolim P, Gerszten RE, Ho CY. Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy. Circ Heart Fail. 2024 Dec; 17(12):e011707.

View in: PubMed
Lee MMY, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Claggett BL, Coats CJ, Gimeno JR, Kulac IJ, Landsteiner I, Ma C, Maron MS, Olivotto I, Owens AT, Solomon SD, Veselka J, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Lewis GD. Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial. JAMA Cardiol. 2024 Nov 01; 9(11):990-1000.

View in: PubMed

People

Explore

Similar Concepts

Top Journals